@article{d75f6b45adfe4f2dbb17fc5ade4e934c,
title = "Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin",
abstract = "The efficacy of aspirin in primary and secondary prevention of cardiovascular diseases has been convincingly demonstrated. Gastrointestinal (GI) adverse effects with aspirin may lead to poor adherence and/or discontinuation of treatment. Proton pump inhibitors (PPIs) have been used for more than 20 years as the first choice for treating peptic ulcers and their bleeding complications, gastroesophageal reflux disease, non-steroidal anti-inflammatory drug-induced GI lesions and dyspepsia. Adherence becomes a major concern when aspirin is co-prescribed with PPIs to prevent GI adverse effects. Combining aspirin and PPIs into one tablet is an effective approach to address aspirin-related GI adverse effects and increase adherence to aspirin therapy for the prevention of cardiovascular diseases.",
keywords = "PA32540, PA8140, antiplatelet therapy, aspirin, combination tablets, proton pump inhibitor",
author = "Gesheff, {Martin G.} and Franzese, {Christopher J.} and Bliden, {Kevin P.} and Contino, {Chase J.} and Rahil Rafeedheen and Tantry, {Udaya S.} and Gurbel, {Paul A.}",
note = "Funding Information: PA Gurbel reports serving as a consultant for Daiichi Sankyo/Lilly, Bayer, AstraZeneca, Accumetrics, Merck, Medtronic, Janssen, CSL and Haemo-netics; receiving grants from the National Institutes of Health, Daiichi Sankyo, Lilly, CSL, AstraZeneca, Haemetics, Harvard Clinical Research Institute and Duke Clinical Research Institute; receiving payment for lectures, including service on speakers{\textquoteright} bureaus, from Lilly, Daiichi Sankyo and Merck; receiving payment for development of educational presentations from Merck, the Discovery Channel and Pri-Med; PA Gurbel is holding stock or stock options in Merck, Medtronic and Pfizer; and holding patents in the area of personalized antiplatelet therapy and interventional cardiology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2014",
month = sep,
doi = "10.1586/17512433.2014.945428",
language = "English (US)",
volume = "7",
pages = "645--653",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "5",
}